Skip to main content

Table 2 Echocardiographic parameters

From: Triptolide improves systolic function and myocardial energy metabolism of diabetic cardiomyopathy in streptozotocin-induced diabetic rats

  Control TP DM DM + TP, L DM + TP, M DM + TP, H
LVEDD, mm 6.4 ± 0.6 6.5 ± 0.7 5.9 ± 0.5 6.0 ± 0.6 5.6 ± 0.6 5.4 ± 0.8
LVEDD index, um/g 13.8 ± 1.6 13.7 ± 2.1 23.6 ± 3.0* 21.1 ± 1.9* 20.2 ± 1.5*# 19.0 ± 1.8*#
LVESD, mm 3.9 ± 0.4 3.8 ± 0.7 3.7 ± 0.6 3.8 ± 0.8 3.3 ± 0.5 3.2 ± 0.8
LVESD index, um/g 8.4 ± 0.8 8.3 ± 0.7 15.8 ± 1.9* 13.5 ± 1.7* 12.9 ± 1.3*# 12.5 ± 1.6*#
LVEF,% 76.4 ± 8.2 78.2 ± 6.3 66.6 ± 6.5* 72.8 ± 5.5 75.0 ± 5.8# 74.6 ± 6.4#
FS,% 44.7 ± 4.3 43.7 ± 5.1 35.8 ± 3.6* 38.9 ± 4.1 41.3 ± 4.9 42.4 ± 4.6
  1. LVEDD left ventricular end-diastolic dimension, LVESD left ventricular end-systolic dimension, LVEF left ventricular ejection fraction, FS fractional shortening. TP,L low-dose triptolide (100 μg/kg/day), TP, M medium-dose triptolide (200 μg/kg/day); TP, H high-dose triptolide (400 μg/kg/day). *P < 0.05 versus Control; #P < 0.05versus DM